Amarin Adrift: Vascepa Label Expansion Doubtful After FDA Drops ANCHOR
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s decision not to reinstate a Special Protocol Assessment for the ANCHOR trial suggests a “complete response” letter on the related sNDA is not far behind.